Table 2.
Summary of driver mutation types
Driver mutation | Total (%) | Type | N (%) |
---|---|---|---|
KRAS | 129 (27) | G12C | 57 (44) |
G12V | 22 (17) | ||
G12D | 15 (12) | ||
G12A | 14 (11) | ||
G12F | 2 (2) | ||
G12R | 1 (1) | ||
G12S | 1 (1) | ||
G13C | 8 (6) | ||
G13D | 1 (1) | ||
Q61H | 4 (3) | ||
Q61L | 2 (2) | ||
Q61R | 1 (1) | ||
A146T | 1 (1) | ||
EGFR | 86 (18) | L858R | 42 (49) |
Exon 19 del. | 39 (45) | ||
L861Q | 2 (2) | ||
S768I | 2 (2) | ||
G719A | 1 (1) | ||
BRAF | 8 (2) | V600E | 6 (75) |
D594G | 2 (25) | ||
PIK3CA* | 8 (2) | E542K | 4 (50) |
C420K | 1 (13) | ||
E545K | 1 (13) | ||
H1047R | 1 (13) | ||
R88Q | 1 (13) | ||
NRAS | 4 (1) | Q61L | 2 (50) |
Q61K | 1 (25) | ||
G31R | 1 (25) | ||
AKT1 | 1 (0.2) | E17K | 1 (100) |
Among PIK3CA mutated tumors, 2 coexisted with KRAS mutation and 2 with EGFR mutation.
EGFR, epidermal growth factor receptor